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ABSTRACT
Background: Some clinical evidence revealed that statins, apart from lowering cholesterol levels, also have an 
antihypertensive effect. Our aim was to evaluate the existence of a possible association of statin therapy with 
blood pressure (BP) control in clinical practice. Materials and Methods: Patients attending a hypertension/
dyslipidemia clinic were prospectively evaluated. Those patients with a diagnosis of stage 1 hypertension 
and hypercholesterolemia who consented to participate were included in the study, either in the statin group 
(when taking a statin) or in the control group (when not taking a statin). Exclusion criteria included dementia, 
pregnancy, or breastfeeding, and history or evidence of stage 2 hypertension. Detailed clinical information was 
prospectively obtained from medical records. A total of 110 hypertensive patients were assigned to the study 
(82 in the statin group and 28 in the control group). Results: Although there were no significant differences 
(P > 0.05) in both groups concerning gender, body mass index, antihypertensive pharmacotherapy, and serum 
levels of high-density lipoprotein cholesterol and triglycerides, a higher BP control was observed in the statin 
group (P = 0.002). Significantly lower systolic BP (−6.7 mmHg, P = 0.020) and diastolic BP (−6.4 mmHg,  
P = 0.002) levels were reported in the statin group. Serum levels of low-density lipoprotein were also significantly 
lower in the statin group (P < 0.001). Conclusions: This observational study detected an association of statin 
therapy with BP control in hypertensive hypercholesterolemic patients in clinical practice. These findings raise 
the possibility that statin therapy may be useful for BP control in the studied population. 
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INTRODUCTION
Hypertension is a major risk factor in the development 
of cardiovascular disease, with myocardial infarction and 
stroke being one of the most important health problems 
worldwide causing excess morbidity and mortality. The risk 
of cardiovascular morbidity and mortality is particularly 
marked when there is insufficient hypertension control and 
prevention at the community level. Randomized controlled 
trials (RCTs) have demonstrated that treating high blood 
pressure (BP) with medication can substantially reduce the 
risk of stroke by 35–40%, myocardial infarction by 20–
25%, and heart failure by more than 50%.[1,2] Hypertension 
is often associated with other cardiovascular risk factors, 
including hypercholesterolemia that are present in over 40% 
of the hypertensive patients.[3] The concomitant presence 
of both hypertension and hypercholesterolemia in the same 
patient is associated with a higher rate of cardiovascular 
events that surpasses the separate contribution of 
each separate risk factor.[4] The prescription of both 
antihypertensive and cholesterol-lowering drugs is generally 
required in these patients.
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Inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A 
reductase (statins) are the most effective and widely used 
cholesterol-lowering agents in industrialized countries.[5] 
They significantly reduce the risk of cardiovascular events, 
particularly in patients showing a combination of high BP 
and hypercholesterolemia.[6] Although the long-term benefit 
of statin therapy is largely attributed to their cholesterol-
lowering action, additional actions of these drugs, which are 
independent from 3-hydroxy-3-methylglutaryl-coenzyme 
A reductase inhibition, are thought to be involved in 
the cardiovascular protection observed shortly after the 
initiation of treatment.[7] Several RCTs have investigated 
the antihypertensive effect of statins in patients with 
hypertension associated with hypercholesterolemia.[8-10] An 
effect of statins on BP is potentially important and not 
improbable considering its reported effects on endothelial 
function, their interaction with the renin–angiotensin 
system, and their ability to affect large artery      compliance.[9,11] 
However, most significant effects of statins on BP control 
were reported in controlled clinical trials,[8-10] which involve 
a highly motivated, closely controlled, and monitored 
patient population, where any supposed antihypertensive 
effects of statins would have a greater chance to be 
detected, when compared to the general population.
The objectives of our study were to prospectively 
investigate, in the setting of clinical practice, the potential 
association of self-administered statins with BP control in 
stage 1 hypertensive outpatients with hypercholesterolemia. 
We, thus, aimed to evaluate the existence of a possible 
relationship between statin therapy and BP control and 
BP levels in hypercholesterolemic hypertensive patients 
attending a hospital outpatient clinic (ambulatory setting) 
for routine follow-up.
MATERIALS AND METHODS
Settings
This study was conducted in a secondary care hypertension/
dyslipidemia clinic in the university teaching hospital 
of Cova da Beira Hospital Centre, Covilhã, District of 
Castelo Branco, located in the Eastern Central Region 
of Portugal. This outpatient clinic is one of the most 
important clinics of this region of Portugal in the field 
of hypertension/dyslipidemia and serves a significant 
hypertensive population of Covilhã, with a population of 
35,000 inhabitants.
Study design
From July 2009 to September 2009, we conducted a cross-
sectional study of patients attending the hypertension/
dyslipidemia medical clinic. All outpatients attending the 
medical clinic during that period were asked to give their 
signed informed consent to be enrolled in the study. The 
study was approved by the institutional ethics committee 
for the use of humans in research, and written informed 
consent was obtained from all participants before their 
enrollment in the study.
Clinical data for this study, including BP measures, lipid 
profile, medications prescribed, and medical problems, 
were prospectively obtained from the Hospital Electronic 
Medical Records (HEMR) database. The HEMR database 
of Cova da Beira Hospital Centre comprises detailed 
patient-level clinical and administrative information of all 
patients who utilized, at least once, this hospital’s services. 
Available information includes patient demographics, 
medical problems, various measures of physiological status, 
and medications prescribed. This database is authorized 
by the Portugal Department of Health, the government 
department responsible for public health issues, and 
patient data confidentiality was ensured. This database was 
accessed at clinic attendance of patients.
Study population
Eligible participants were all adults (aged ≥18 years) 
with an established medical diagnosis of stage 1 
hypertension (BP measurements, in the clinic, of systolic 
BP 140–159 mmHg and/or diastolic BP 90–99 mmHg, 
as defined in current international guidelines[12]) and 
hypercholesterolemia (fasting total serum cholesterol 
≥200 mg/dL). Furthermore, all included patients had been 
on established antihypertensive treatment for at least 6 
months. The recruited hypertensive hypercholesterolemic 
patients were included either in the statin group (when 
taking a statin for at least 6 months) or in the control 
group (when not taking a statin) and BP control and BP 
levels of both groups were compared. Exclusion criteria 
included dementia, pregnancy, or breastfeeding, and history 
or evidence of stage 2 hypertension (BP measurements, in 
the clinic, of systolic BP ≥ 160 mmHg and/or diastolic BP 
≥ 100 mmHg). Hypertensive hypercholesterolemic patients 
taking a statin for less than 6 months were also excluded.
BP measurements
BP was measured in a seated position after a 5-min 
rest period, using a mercury sphygmomanometer or 
automatic device (Omron M4-I), with the mean of two 
consecutive measurements spaced by 1–2 min. Additional 
measurements were taken if the first two were quite 46 Journal of Cardiovascular Disease Research Vol. 2 / No 1
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was 0.71 for the five-item scale,[13] better than the 0.61 for 
the original four-item scale.[14]
Statistical analysis
Demographic variables, clinical data, BP values, and 
lipid profile of patients included in the study, and also 
prescribing metrics were examined on a descriptive basis 
and expressed as the mean ± SD (standard deviation), 
frequency, and percentages. Student’s t-test and Mann–
Whitney rank-sum test were used to compare continuous 
variables and χ2-test and Fisher’s exact test were used to 
test for differences between categorical variables. A logistic 
regression model was used to adjust the odds ratio (OR) of 
controlled BP associated with statin therapy for the length 
of antihypertensive treatment. All statistical analyses were 
carried out using SPSS for Windows, version 17.0 (SPSS 
Inc., Chicago, IL, USA), and a P-value of less than 0.05 
was considered to indicate statistical significance.
RESULTS
A total of 222 patients attended the medical clinic during 
different. The BP clinic measurement was performed by 
several nurses blinded to the study.
According to the seventh report of the Joint National 
Committee on the Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure (JNC 7), hypertensive 
patients without diabetes and chronic kidney disease (CKD) 
with BP <140/90 mmHg were considered to have their 
BP controlled.[1] For hypertensive patients with diabetes 
or CKD, BP control was defined as BP measurements 
<130/80 mmHg.[1]
Medication adherence assessment
The assessment of medication adherence was determined 
using a validated five-item compliance scale[13] derived 
from the four-item scale developed by Morisky et al.[14,15] 
Low medication adherence was defined as answering ‘yes’ 
to three or more of five questions.[13] The five-item scale 
was reported to have predictive validity in that it was able 
to discriminate levels of hypertension control[14] and to 
discriminate cases of hypertensive emergency or urgency 
from hypertensive controls.[16] Cronbach’s coefficient 
alpha,[17] a measure of the internal consistency of the scale, 
Figure 1: Diagram of patient enrollment47 Journal of Cardiovascular Disease Research Vol. 2 / No 1
Morgado, et al.: Reduction of blood pressure with statins
the recruitment period (from July 2009 to September 
2009), and all were assessed for eligibility. Of these, 76 
were excluded from our study because they did not meet 
the inclusion criteria, 28 were excluded because of stage 2 
hypertension, 1 was excluded because of breastfeeding, and 
7 were excluded because they declined to participate (did 
not sign the informed consent). Of the 110 hypertensive 
hypercholesterolemic patients meeting the inclusion criteria 
and consenting to participate, 82 were included in the statin 
group and 28 were included in the control group [Figure 1].
The overall mean age of the included patients was 59.7 
± 9.5 years, 40.0% being male and 60.0% female. Among 
these hypertensive hypercholesterolemic patients, 82 (74.5%) 
were taking a prescribed statin for at least 6 months and 
were included in the statin group, whereas the remaining 28 
(25.5%) were not taking a statin and were included in the 
control group [Table 1]. In the statin group, patients were 
receiving both dietary advice and a statin. In the control group, 
patients were receiving dietary advice alone as a therapeutic 
measure to control hypercholesterolemia. The use of a 
statin was considered only when dietary measures alone had 
proven to be insufficient to control hypercholesterolemia. 
All statins currently licensed for human use in Portugal were 
prescribed (atorvastatin, fluvastatin, lovastatin, pravastatin, 
rosuvastatin, and simvastatin). 
There were no significant differences between patients 
in the statin group and the control group concerning age 
(mean 60.2 ± 9.6 years vs. 58.1 ± 9.4 years; P = 0.306), 
gender (39.0% males vs. 42.9%; P = 0.718), and body 
mass index (mean 29.8 ± 4.7 kg/m2 vs. 29.8 ± 4.6 kg/
m2; P = 0.963). Likewise, the proportion of patients with 
diabetes and/or chronic kidney disease, the number and 
class of antihypertensive drugs used, and the high-density 
lipoprotein cholesterol (HDL-C) and triglyceride fasting 
serum levels did not significantly differ in both groups. 
Conversely and as expected, fasting total serum cholesterol 
and low-density lipoprotein cholesterol (LDL-C) levels 
were significantly lower in the statin group. In addition, 
the mean duration of antihypertensive drug treatment was 
significantly higher in the statin group (10.1 vs. 6.9 years, 
P = 0.031), which might represent a possible confounding 
variable [Table 1]. 
Blood pressure control according to the JCN 7 guidelines 
was significantly higher (P = 0.002) in the statin group 
(54.9%) when compared with the control group (21.4%; 
Table 1). Accordingly,  significantly lower systolic BP (−6.7 
mmHg, P = 0.020) and diastolic BP (−6.4 mmHg, P = 
0.002) levels were observed in the statin group [Figure 2]. 
In the light of these results, since the mean duration of 
Table 1: Clinical characteristics of the study population
Characteristics Statin group
(n = 82)
Control group
(n = 28)
P-value for difference
Mean age (years) 60.2 ± 9.6 58.1 ± 9.4 0.306
Gender (male/female; %) 39.0/61.0 42.9/57.1 0.718
Body mass index (kg/m2) 29.8 ± 4.7 29.8 ± 4.6 0.963
Loop diuretics (%) 15.9 10.7 0.560
Thiazide diuretics (%) 58.5 64.3 0.590
Potassium-sparing diuretics (%) 2.4 3.6 1
Renin inhibitors (%) 1.2 0.0 1
ACE inhibitors (%) 34.1 39.3 0.624
Angiotensin II receptor antagonists (%) 56.1 53.6 0.823
Calcium channel blockers (%) 41.5 25.0 0.120
Beta blockers (%) 45.1 39.3 0.590
Central alpha-2 agonists (%) 7.3 0.0 0.199
Number of antihypertensive drugs per patient 2.6 ± 1.5 2.4 ± 1.1 0.401
Number of years in antihypertensive drug treatment 10.1 ± 7.1 6.9 ± 4.2 0.031*
Total cholesterol (mg/dL) 185.5 ± 39.5 221.3 ± 52.1 <0.001*
LDL cholesterol (mg/dL) 107.1 ± 36.2 140.5 ± 40.9 <0.001*
HDL cholesterol (mg/dL) 50.8 ± 11.7 47.4 ± 8.4 0.169
Triglyceride (mg/dL) 141.9 ± 61.1 172.3 ± 105.0 0.074
Diabetes or chronic kidney disease (%) 22.0 17.9 0.647
BP controlled (JCN 7 guidelines) (%) 54.9 21.4 0.002*
Low, self-reported medication adherence, score ≥ 3 (%) 47.6 57.1 0.380
Values are mean ± SD unless otherwise stated, *statistically significant difference (P-value < 0.05), ACE, Angiotensin-converting enzyme; BP, Blood pressure; HDL, High-
density lipoprotein; LDL, low-density lipoprotein 48 Journal of Cardiovascular Disease Research Vol. 2 / No 1
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antihypertensive drug treatment was significantly higher 
in the statin group, this variable was included into a 
logistic regression model to adjust the OR of controlled 
BP associated with statin therapy in hypertensive 
hypercholesterolemic patients [Table 2].
The crude model presented in Table 2 confirms that statin 
therapy increases the likelihood of having the BP controlled 
[OR 4.46; 95% confidence interval (CI) 1.64–12.15]. After 
adjusting for the length of antihypertensive treatment, the 
same statistically significant relationship is observed [OR 
5.23; 95% CI 1.86–14.67], confirming the hypothesis that 
statin therapy may be useful for BP control in the studied 
population.
DISCUSSION
Previous studies found a possible relationship between 
hyperlipidemia and hypertension that coexist very often 
in the same patients and exert a cumulative effect on the 
risk of cardiovascular events.[3,18,19] Several RCTs revealed 
that statins, beyond their lipid-lowering properties, are also 
able to significantly reduce systolic and diastolic BP.[8-10,20] 
However, the capacity of statins to affect systemic BP in 
clinical practice is still debated and a demonstration of a 
better BP control, according to JNC 7 guidelines, in self-
administered hypertensive, hypercholesterolemic statin 
outpatients is still lacking. The data recently provided by 
the Plaque Hypertension Lipid-Lowering Italian Study 
(PHYLLIS) trial, which enrolled both stage 1 and 2 
hypertensive hypercholesterolemic patients (systolic BP 
150–210 mmHg and diastolic BP 95–115 mmHg), do not 
confirm the conclusion of previous studies that statins 
exert a BP-lowering effect.[21] The results of PHYLLIS 
revealed that the administration of a statin in hypertensive 
hypercholesterolemic patients in whom BP is effectively 
reduced by concomitant antihypertensive treatment does 
not have an additional BP-lowering effect,[21] which seems 
to be in line with a few previous studies.[22,23]
In this cross-sectional study, statin therapy was not 
only associated with an improved lipid profile, through 
significantly lower fasting total serum cholesterol and 
LDL-C levels, but also with a higher BP control in stage 
1 hypertensive hypercholesterolemic patients from the 
Eastern Central Region of Portugal. After adjusting for 
the length of antihypertensive treatment, statin therapy 
increased 5.23 times the odds of having the BP controlled, 
this relationship being statistically significant (95% CI 
1.86–14.67). The magnitude of systolic and diastolic BP 
reduction (−6.7 mmHg and −6.4 mmHg, respectively, P 
< 0.05) observed in the statin group when compared to 
the control group is in agreement with data obtained in 
some RCTs.[24] 
These findings may have some reasonable clinical 
implications since they help to emphasize the role of statins 
in the prevention of cardiovascular diseases, particularly 
in hypertensive hypercholesterolemic patients with stage 
1 arterial hypertension. However, adequately powered 
epidemiological studies need to be considered to test the 
efficacy and safety of statin therapy in BP control and 
prevention of cardiovascular events.
Several limitations of this study must be mentioned. First, 
the sample size power to detect small differences between 
groups may be questionable. Even though the association 
observed is statistically significant, the increased precision 
of confidence intervals is desired. From a methodological 
point of view, this is a small cross-sectional study and our 
results must be considered exploratory in nature. Second, 
the evaluation of BP control is also subject to criticism 
since it is based on the measurements performed in one 
single medical appointment. These BP measurements may 
or may not be representative of the adequacy of BP control 
in hypertensive patients. Third, we were unable to obtain 
objective measurements of patient medication compliance 
Table 2: Odds ratio of controlled BP associated 
with statin therapy according to the length of 
antihypertensive treatment
Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)*
Statin therapy 4.46 (1.64–12.15)† 5.23 (1.86–14.67)†
*Results are adjusted for the length of antihypertensive treatment, †Values are 
significant at the 0.05 level (two-sided), CI, confidence interval; OR, odds ratio.
Figure 2: Significant lower systolic blood pressure (−6.7 mmHg,   
P = 0.020) and diastolic blood pressure (−6.4 mmHg, P = 0.002) levels 
were observed in the statin group when compared with the control 
group. Error bars indicate standard deviation. BP, blood pressure49 Journal of Cardiovascular Disease Research Vol. 2 / No 1
Morgado, et al.: Reduction of blood pressure with statins
(e.g., drug level in biologic fluids, biologic markers, direct 
patient observation) and compare them in both groups. 
Finally, we did not evaluate whether some combinations 
of certain statins and antihypertensive drugs might result 
in a more effective BP control than others, and we did not 
investigate whether the effect of statins on BP was dose 
related or not.
In conclusion, our results are aligned with the majority of 
the medical literature suggesting a statistically significant 
BP-lowering effect of statins, feasible to be achieved in 
hypertensive hypercholesterolemic patients in a clinical 
practice setting. Our findings suggest that, in stage 1 
hypertensive patients in whom the prescription of a statin 
is simultaneously indicated (e.g., because of concomitant 
hypercholesterolemia), this can improve BP control 
and reduce, to some extent, the dose and number of 
antihypertensive drugs required to achieve satisfactory 
hypertension control. Therefore, our findings might have 
useful implications for effective and safe prevention of 
cardiovascular events, particularly in stage 1 hypertensive 
hypercholesterolemic patients in whom BP is not effectively 
controlled solely by concomitant antihypertensive 
treatment. Further studies are needed in this population 
to clarify the exact magnitude of the effect of statins on 
BP control, as well as its clinical relevance.
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